WNT5A and benign prostatic hyperplasia: Assessment of immunohistochemical staining intensity through digital image analysis, corroborated by statistical testing, confirmed lower immunoreactivity of β-catenin, Fzd8, Wnt5a and cyclin D1 in prostate adenocarcinoma compared to benign prostatic hyperplasia.